医学
粒细胞集落刺激因子
免疫学
移植物抗宿主病
北京
协议(科学)
移植
干细胞
内科学
中国
生物
病理
化疗
法学
替代医学
遗传学
政治学
作者
Zhengli Xu,Xiao‐Jun Huang
出处
期刊:Blood Reviews
[Elsevier]
日期:2023-11-01
卷期号:62: 101035-101035
被引量:6
标识
DOI:10.1016/j.blre.2022.101035
摘要
Haploidentical donor stem cell transplantation (haplo-SCT) has made great advances in recent decades. The granulocyte colony-stimulating factor (G-CSF)- and antithymocyte globulin (ATG)-based protocol, which is known as the Beijing Protocol, represents one of the current T-cell repletion strategies in haplo-SCT. The key elements of the Beijing Protocol for graft versus host disease (GvHD) prophylaxis include G-CSF inducing T-cell tolerance and altering graft cell components, as well as ATG administration exerting an immunoregulatory effect for intensive prophylaxis. This review will summarize the GvHD incidence, the underlying novel mechanism for GvHD prophylaxis, how to optimize GvHD prophylaxis, and the recent advances of the Beijing Protocol, mainly focusing on the issues of GvHD.
科研通智能强力驱动
Strongly Powered by AbleSci AI